截至本公告披露日，张建辉先生持有公司股份568.04万股，占公司总股本的4.61%；张建辉先生不存在 应当履行而未履行的承诺事项。 格隆汇9月10日丨金迪克(688670.SH)公布，公司董事会沉痛哀告：公司收到公司总经理张建辉先生家属 通知，张建辉先生因病于近日不幸逝世，享年67岁。 张建辉先生自2015年起一直为公司或公司前身江苏金迪克生物技术有限公司的主要股东之一，并于2023 年10月被聘任为公司总经理。张建辉先生长期伴随并支持公司发展壮大；在担任公司总经理期间，勤勉 尽责、恪尽职守，认真履行了作为公司高级管理人应尽的责任和义务，为公司经营发展做出了重要贡 献。公司董事会、监事会、高级管理人员及全体员工对张建辉先生为公司所做的努力和贡献深表感谢， 对张建辉先生的逝世致以沉痛哀悼，并向其家属致以深切慰问。 目前公司生产经营一切正常，公司董事会推举董事长余军先生代行总经理职责，公司董事会将根据《中 华人民共和国公司法》和《公司章程》的规定，尽快完成公司总经理聘任工作，并及时履行信息披露义 务。责任编辑：钟离 ...

Core Viewpoint - The company, Jindike (688670.SH), announced the unfortunate passing of its General Manager, Mr. Zhang Jianhui, due to illness at the age of 67 [1] Company Summary - Jindike has received notification from the family of Mr. Zhang Jianhui regarding his death [1]

Group 1 - The company, Jindike (688670.SH), announced the unfortunate passing of its general manager, Mr. Zhang Jianhui, due to illness, at the age of 67 [1]

证券代码：688670 证券简称：金迪克 公告编号：2025-024 目前公司生产经营一切正常，公司董事会推举董事长余军先生代行总经理 职责，公司董事会将根据《中华人民共和国公司法》和《公司章程》的规定， 尽快完成公司总经理聘任工作，并及时履行信息披露义务。 公司董事、监事、高级管理人员及全体员工将化悲痛为力量，团结一心， 继续推进公司的持续健康发展。 特此公告。 江苏金迪克生物技术股份有限公司 江苏金迪克生物技术股份有限公司 关于公司总经理逝世的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏金迪克生物技术股份有限公司（以下简称"公司"）董事会沉痛哀告： 公司收到公司总经理张建辉先生家属通知，张建辉先生因病于近日不幸逝世， 享年 67 岁。 张建辉先生自 2015 年起一直为公司或公司前身江苏金迪克生物技术有限公 司的主要股东之一，并于 2023 年 10 月被聘任为公司总经理。张建辉先生长期 伴随并支持公司发展壮大；在担任公司总经理期间，勤勉尽责、恪尽职守，认 真履行了作为公司高级管理人应尽的责任和义务，为公 ...

Core Viewpoint - The company announced the unfortunate passing of its General Manager, Zhang Jianhui, due to illness, highlighting his significant contributions to the company's development since 2015 [1] Group 1 - Zhang Jianhui served as a major shareholder and was appointed General Manager in October 2023 [1] - The company expressed deep condolences and gratitude for Zhang Jianhui's dedication and efforts during his tenure [1] - As of the announcement date, Zhang Jianhui held 5.6804 million shares, representing 4.61% of the company's total equity [1] Group 2 - The company's operations remain normal following the announcement [1] - The board of directors has appointed Chairman Yu Jun to act as the General Manager temporarily [1] - The company will expedite the process of appointing a new General Manager in accordance with relevant laws and regulations [1]

Core Points - The company announced the unfortunate passing of General Manager Zhang Jianhui due to illness at the age of 67 [1] - Zhang Jianhui was a major shareholder since 2015 and was appointed as General Manager in October 2023 [1] - As of the announcement date, Zhang Jianhui held 5.6804 million shares, representing 4.61% of the company's total equity [1] - The company's operations are currently normal, and the board has appointed Chairman Yu Jun to act as General Manager temporarily [1] - The company plans to complete the appointment of a new General Manager as soon as possible [1]

Core Viewpoint - The China Food and Drug Administration has approved the first batch of the quadrivalent influenza vaccine from Jindike for 2025 [1] Company Summary - Jindike's quadrivalent influenza vaccine has received regulatory approval, indicating progress in the company's vaccine development efforts [1] Industry Summary - The approval of the influenza vaccine reflects ongoing advancements in the pharmaceutical industry, particularly in vaccine development and public health initiatives [1]

据证券之星公开数据整理，近期金迪克（688670）发布2025年中报。截至本报告期末，公司营业总收入 352.42万元，同比上升7.18%，归母净利润-3965.31万元，同比上升2.97%。按单季度数据看，第二季度 营业总收入6.04万元，同比上升103.49%，第二季度归母净利润-2207.18万元，同比下降13.91%。本报告 期金迪克存货明显上升，存货同比增幅达83.9%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率94.77%，同比增21.99%，净利率-1125.15%，同 比增9.47%，销售费用、管理费用、财务费用总计3454.96万元，三费占营收比980.34%，同比减 30.86%，每股净资产10.05元，同比减6.94%，每股经营性现金流-0.69元，同比增4.24%，每股收益-0.32 元，同比增3.03% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 328.82万 | 352.42万 | 7.18% | | 归母浄利润（元） | -4086.71万 | -3965.31万 | ...

Summary of Key Points Core Viewpoint - The financing activities of Jindike (688670) indicate a positive sentiment among investors, with a net buying trend observed over recent trading days, suggesting potential growth in stock value [1][2]. Financing Activities - On August 21, 2025, Jindike had a financing buy of 239.03 thousand yuan and a financing repayment of 190.06 thousand yuan, resulting in a net financing purchase of 48.97 thousand yuan [1]. - The financing balance reached 2295.64 thousand yuan, with a net buying total of 257.72 thousand yuan over the last three trading days [1][2]. - In the last 20 trading days, there were 12 days with net financing purchases, indicating sustained investor interest [1]. Financing Balance Trends - The financing balance increased by 2.18% on August 21, 2025, compared to the previous day [3]. - The financing balance on August 20 was 2246.67 thousand yuan, showing a daily increase of 31.61 thousand yuan, which was a 1.43% rise [3]. - The highest net financing purchase in the observed period was 177.14 thousand yuan on August 19, contributing to an 8.69% increase in the financing balance [3]. Margin Trading Knowledge - Financing refers to the practice where securities companies lend money to investors to purchase stocks, while margin trading allows investors to borrow stocks to sell, expecting to buy them back at a lower price [4].

Core Insights - Jindike (688670.SH) released its semi-annual report for 2025 on August 22, 2025, indicating a total of 4 institutional investors holding shares, amounting to 4.0434 million shares, which represents 3.28% of the total share capital [1] - The institutional holding percentage decreased by 0.33 percentage points compared to the previous quarter [1] Institutional Investors - The institutional investors include Taizhou Tongze Enterprise Management Consulting Partnership (Limited Partnership), Taizhou Tongren Enterprise Management Consulting Partnership (Limited Partnership), Tianjin Qiuyang Growth Private Fund Management Co., Ltd. - Qiuyang Boying No. 1 Private Securities Investment Fund, and Qianhai Kaiyuan Strong Consensus Top 100 Stocks [1] - The total institutional holding percentage stands at 3.28% [1] Public Funds - One new public fund disclosed during this period is Qianhai Kaiyuan Strong Consensus Top 100 Stocks [1]